Skip to main content

Market Overview

Oncolytics Biotech's Pelareorep Associated With Therapeutic Efficacy, Improved Clinical Outcomes In Breast Cancer

Share:
Oncolytics Biotech's Pelareorep Associated With Therapeutic Efficacy, Improved Clinical Outcomes In Breast Cancer
  • Oncolytics Biotech Inc (NASDAQ: ONCY), together with SOLTI, has announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study evaluating pelareorep plus checkpoint blockade therapy. 
  • These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.
  • Data from 20 HR+/HER2- early-stage breast cancer patients included in AWARE-1's first two cohorts are presented.
  • These patients were treated with pelareorep and letrozole without (cohort 1) or with (cohort 2) Roche's PD-L1 inhibitor atezolizumab (Tecentriq) before surgery.
  • Pelareorep treatment in cohort 1 induced the generation and expansion of T cell clones, promoted tumor infiltration of CD8+ T cells, and increased the CelTIL score, a measure of tumor cellularity and inflammation associated with favorable clinical outcomes.
  • Data from cohort 2 patients demonstrated that pelareorep and atezolizumab generated an anti-cancer immune response in the tumor and peripheral blood.
  • Notably, cohort 2 met the pre-specified success criteria for the study's primary endpoint (50% of patients with over 30% increase in CelTIL score)—six of ten patients achieved at least a 30% increase in CelTIL score following treatment.
  • Pelareorep reversed immunosuppressive tumor microenvironments and promoted immune effector cell infiltration into solid tumors.
  • Tumor-cell-specific pelareorep replication was observed in all evaluated patients following intravenous pelareorep administration.
  • 70% of all cohort 1 and 2 patients (n=20) saw an increase in CelTIL from baseline to surgery.
  • Compared to cohort 1, cohort 2 patients had a higher ratio of CD8+ T cells to regulatory T cells, suggesting pelareorep and checkpoint inhibition enhance inflammation within the tumor microenvironment.
  • Oncolytics will host a Key Opinion Leader event today at 2:00 pm E.T.
  • Price Action: ONCY shares are down 8.9% at $3.65 on the last check Monday.
 

Related Articles (ONCY)

View Comments and Join the Discussion!

Posted-In: breast cancer BriefsBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com